InvestSMART

EMvision Medical Devices Limited (ASX: EMV) - Announcements

- Current share price for EMV : $1.725

ASX company news and announcements for EMvision Medical Devices Limited (EMV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All EMvision Medical Devices Limited (EMV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than EMvision Medical Devices Limited (EMV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for EMvision Medical Devices Limited (EMV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$160 AGM Chairman's Address & Presentation 25 Nov 2021 1:34PM $2.710 $1.725 fallen by 36.35%
$160 Advance QLD Industry Fellowship Win 24 Nov 2021 8:15AM $2.700 $1.725 fallen by 36.11%
$160 Quarterly Activities/Appendix 4C Cash Flow Report 28 Oct 2021 10:06AM $2.880 $1.725 fallen by 40.10%
$160 Notice of Annual General Meeting/Proxy Form 26 Oct 2021 1:32PM $2.940 $1.725 fallen by 41.33%
$160 Investor Presentation - Morgans Scone Conference 21 Oct 2021 9:08AM $2.970 $1.725 fallen by 41.92%
$160 Brain Scanner Published in Peer-Reviewed Medical Journal 18 Oct 2021 9:42AM $2.960 $1.725 fallen by 41.72%
$160 FDA Breakthrough Device Application Update 6 Oct 2021 8:22AM $3.070 $1.725 fallen by 43.81%
$160 Cleansing Notice 1 Oct 2021 5:32PM $3.250 $1.725 fallen by 46.92%
$160 Application for quotation of securities - EMV 1 Oct 2021 5:29PM $3.250 $1.725 fallen by 46.92%
$160 Date of AGM & Closing Date For Director Nominations 28 Sep 2021 8:22AM $3.000 $1.725 fallen by 42.50%
$160 ASA & EMVision Sign $8m Project Agreement 16 Sep 2021 8:48AM $2.820 $1.725 fallen by 38.83%
$160 Appendix 4G & Corporate Governance Statement 31 Aug 2021 4:35PM $3.000 $1.725 fallen by 42.50%
$160 Appendix 4E & Annual Report 30 June 2021 31 Aug 2021 4:35PM $3.000 $1.725 fallen by 42.50%
$160 Notification of cessation of securities - EMV 19 Aug 2021 5:14PM $2.980 $1.725 fallen by 42.11%
$160 Cleansing Notice 17 Aug 2021 4:57PM $3.000 $1.725 fallen by 42.50%
$160 Application for quotation of securities - EMV 17 Aug 2021 4:49PM $3.000 $1.725 fallen by 42.50%
$160 1st Gen Device Successfully Manufactured & Ready for Testing 10 Aug 2021 8:55AM $2.630 $1.725 fallen by 34.41%
$160 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2021 9:42AM $2.640 $1.725 fallen by 34.66%
$160 EMVision 1st Generation Device Progressing Well 20 Jul 2021 8:34AM $2.750 $1.725 fallen by 37.27%
$160 Cleansing Notice 30 Jun 2021 5:19PM $3.010 $1.725 fallen by 42.69%
$160 Application for quotation of securities - EMV 30 Jun 2021 5:13PM $3.010 $1.725 fallen by 42.69%
$160 Clinical Research Partnership Signed with Metro South Health 21 Jun 2021 9:22AM $3.010 $1.725 fallen by 42.69%
$160 Application for quotation of securities - EMV 16 Jun 2021 5:27PM $3.130 $1.725 fallen by 44.89%
$160 Brain Scanner Development Update 24 May 2021 9:09AM $2.850 $1.725 fallen by 39.47%
$160 Appendix 2A & Cleansing Notice 18 May 2021 5:27PM $2.900 $1.725 fallen by 40.52%

226 - 250 of 375 results

Page 10 of 15

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.